These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26529549)

  • 1. Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.
    Bellecave P; Recordon-Pinson P; Fleury H
    AIDS Res Hum Retroviruses; 2016 Jan; 32(1):85-92. PubMed ID: 26529549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants.
    Perrier M; Désiré N; Storto A; Todesco E; Rodriguez C; Bertine M; Le Hingrat Q; Visseaux B; Calvez V; Descamps D; Marcelin AG; Charpentier C
    PLoS One; 2018; 13(6):e0198334. PubMed ID: 29856864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit.
    Stelzl E; Pröll J; Bizon B; Niklas N; Danzer M; Hackl C; Stabentheiner S; Gabriel C; Kessler HH
    J Virol Methods; 2011 Dec; 178(1-2):94-7. PubMed ID: 21907239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory.
    Ram D; Leshkowitz D; Gonzalez D; Forer R; Levy I; Chowers M; Lorber M; Hindiyeh M; Mendelson E; Mor O
    J Virol Methods; 2015 Feb; 212():12-6. PubMed ID: 25445792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of an
    Tzou PL; Ariyaratne P; Varghese V; Lee C; Rakhmanaliev E; Villy C; Yee M; Tan K; Michel G; Pinsky BA; Shafer RW
    J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29618499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
    Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
    J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of publicly-available software used in analyzing NGS data for HIV-1 drug resistance mutations and transmission networks in a Washington, DC, Cohort.
    Jair K; McCann CD; Reed H; Castel AD; Pérez-Losada M; Wilbourn B; Greenberg AE; Jordan JA;
    PLoS One; 2019; 14(4):e0214820. PubMed ID: 30964884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay.
    Alidjinou EK; Coulon P; Hallaert C; Robineau O; Meybeck A; Huleux T; Ajana F; Hober D; Bocket L
    J Clin Virol; 2019 Dec; 121():104207. PubMed ID: 31707202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Evaluation of the Vela Diagnostics Next-Generation Sequencing Platform for HIV-1 Genotypic Resistance Testing.
    Weber J; Volkova I; Sahoo MK; Tzou PL; Shafer RW; Pinsky BA
    J Mol Diagn; 2019 Nov; 21(6):961-970. PubMed ID: 31382033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detecting primary drug-resistant mutations in Korean HIV patients using ultradeep pyrosequencing.
    Cho MC; Park CW; Park BG; Oh HB; Choi SH; Choi SE; Cho NS
    J Virol Methods; 2016 Aug; 234():115-22. PubMed ID: 27109046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
    Gholami M; Rouzbahani N; Samiee S; Tayeri K; Ghorban K; Dehkharghani AD; Gholami AA; Moshiri F; Sattari A; Dadmanesh M; Mohraz M
    Microb Pathog; 2020 Sep; 146():104221. PubMed ID: 32360523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer.
    Eshleman SH; Crutcher G; Petrauskene O; Kunstman K; Cunningham SP; Trevino C; Davis C; Kennedy J; Fairman J; Foley B; Kop J
    J Clin Microbiol; 2005 Feb; 43(2):813-7. PubMed ID: 15695685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples.
    Trabaud MA; Icard V; Ramière C; Tardy JC; Scholtes C; André P
    J Med Virol; 2017 Nov; 89(11):1912-1919. PubMed ID: 28590068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV drug resistance surveillance using pooled pyrosequencing.
    Ji H; Massé N; Tyler S; Liang B; Li Y; Merks H; Graham M; Sandstrom P; Brooks J
    PLoS One; 2010 Feb; 5(2):e9263. PubMed ID: 20174661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing.
    Alteri C; Santoro MM; Abbate I; Rozera G; Bruselles A; Bartolini B; Gori C; Forbici F; Orchi N; Tozzi V; Palamara G; Antinori A; Narciso P; Girardi E; Svicher V; Ceccherini-Silberstein F; Capobianchi MR; Perno CF
    J Antimicrob Chemother; 2011 Nov; 66(11):2615-23. PubMed ID: 21890537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Vela Diagnostics HIV-1 genotyping assay on an automated next generation sequencing platform.
    May S; Adamska E; Tang J
    J Clin Virol; 2020 Jun; 127():104376. PubMed ID: 32344322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors.
    Dalmat RR; Makhsous N; Pepper GG; Magaret A; Jerome KR; Wald A; Greninger AL
    J Clin Microbiol; 2018 Dec; 56(12):. PubMed ID: 30305383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform.
    Raymond S; Nicot F; Carcenac R; Lefebvre C; Jeanne N; Saune K; Delobel P; Izopet J
    J Antimicrob Chemother; 2018 May; 73(5):1152-1157. PubMed ID: 29444253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance.
    Steegen K; Demecheleer E; De Cabooter N; Nges D; Temmerman M; Ndumbe P; Mandaliya K; Plum J; Verhofstede C
    J Virol Methods; 2006 May; 133(2):137-45. PubMed ID: 16375980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.